A groundbreaking study published in Nature Communications highlights a promising new COVID-19 vaccine candidate, MV-014-212, developed as an intranasal live attenuated recombinant vaccine. This vaccine, which expresses a chimeric SARS-CoV-2 spike protein, has shown significant promise in preclinical trials, offering a potential pathway for broader and more effective COVID-19 immunization strategies.
The study, led by researchers exploring novel vaccine platforms, introduces MV-014-212, which is derived from the human respiratory syncytial virus (RSV). By replacing the RSV surface glycoproteins with a modified SARS-CoV-2 spike protein, the vaccine provides both systemic and mucosal immunity, which is crucial for preventing early-stage viral infection in the upper respiratory tract.
One of the most notable aspects of the study is the involvement of Avance Biosciences, who performed the critical RNA sequencing used in the study. Through their high-precision sequencing capabilities, Avance provided valuable genomic insights that allowed researchers to assess the vaccine’s genetic stability and effectiveness across different virus variants.
In animal trials conducted on African green monkeys, a single intranasal dose of MV-014-212 significantly reduced viral shedding by more than 200-fold compared to control groups, showcasing its potential to limit the spread of SARS-CoV-2. This attenuation of viral shedding was also observed to persist for extended periods, highlighting the robustness of the immune response induced by the vaccine. Furthermore, the vaccine elicited cross-neutralizing antibodies against the Alpha, Beta, and Delta variants, underscoring its broad-spectrum protection.
Live attenuated vaccines, such as MV-014-212, have the added advantage of mimicking natural infection, making them capable of stimulating a stronger immune response, particularly in mucosal tissues where viruses typically first enter the body. This is a critical feature for respiratory viruses like SARS-CoV-2, where mucosal immunity plays a key role in preventing initial infection.
The study’s promising results pave the way for future clinical trials, with MV-014-212 currently undergoing Phase 1 evaluation. The vaccine’s potential for low-cost, global deployment could prove vital in the ongoing fight against COVID-19, particularly in regions with limited access to more conventional vaccine options.
Avance Biosciences continues to support cutting-edge research in the fight against COVID-19, and their RNA sequencing expertise remains integral in the development of vaccines like MV-014-212. With this partnership, the study moves closer to offering a new, innovative solution to help curb the spread of the pandemic.
As we move forward, the next steps will involve clinical testing, and the research community eagerly anticipates the results of these trials, which could mark a new chapter in vaccine technology.
Tioni MF, Jordan R, Pena AS, Garg A, Wu D, Phan SI, Weiss CM, Cheng X, Greenhouse J, Orekov T, Valentin D, Kar S, Pessaint L, Andersen H, Stobart CC, Bloodworth MH, Stokes Peebles R, Liu Y, Xie X, Shi PY, Moore ML, Tang RS. (2022) Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2 NPJ Vaccines . 2022 Jul 29;7(1):85. DOI: doi: 10.1038/s41541-022-00509-6.
When you partner with Avance Biosciences™, you gain a CRO partner that is creative, collaborative and dedicated to sound science with a focus on the regulatory requirements our partners require. Contact our technical staff to discuss how we can support you in your project!
